North America’s BEST Small Cap Stock Ideas
A few weeks ago, we wrote Hemispherx Biopharma’s (HEB – $2.73) shares were on a rollercoaster and it seems the ride is getting wilder and wilder. Obviously, there’s a tremendous amount of speculation about the FDA’s decision to approve Ampligen for Chronic Fatigue Syndrome (CFS). Based on all the public information out there, you have to form an opinion, and […]
Read moreWe recommended Orsus Xelent Technologies Inc. (ORS – $0.91) on January 10, 2009, at $0.47 as one of our three stocks for 2009. Although there was no real catalyst, the stock went up almost 50% this week. The Company did report strong first quarter results on May 20th and this week’s jump may be a late reaction to it. We […]
Read moreFor many this is starting to look like a soap opera, but contrary to the TV version, this is extremely exciting. Obviously, we’re talking about Hemispherx Biopharma (HEB) and the big question will the FDA give its thumbs up to bring Ampligen to the market. The introduction to the next episode was given on Tuesday morning when HEB issued a […]
Read moreOrsus Xelent Technologies, Inc. (ORS) our designer and manufacturer of mobile phones for the Asian market, announced that its first quarter revenues declined about 4.8% compared with the same period last year to $19.7 million. However, the Company’s net income rose 11.4% to $2.2 million or 7 cents per share. In these market circumstances, that’s a great performance! These numbers […]
Read moreMost Hemispherx Biopharma (HEB) shareholders must be feeling sick after being on a rollercoaster ride an entire week. The stock went up and down and traded more than 90 million shares only to finish 1 cent below where it closed last Friday. Two months ago, barely 200,000 shares changed hands in a week’s time. On Tuesday, the Company announced a […]
Read moreIn this update report (pdf) we discuss Acme United’s (ACU – $7.42) first quarter results. We explain why we feel this stock is undervalued at current levels and we give an outlook for the near term future. Underneath are a few highlights from the report: Even in these difficult market circumstances, the Company was able to gain 5 large mass […]
Read moreAt last week’s National Hardware Show in Las Vegas, the world renowned Camillus Cutlery was re-launched. This may not seem like a big event at first, but if you know a little bit about this Company’s history, it is. For more than a hundred years, Camillus was dedicated to produce the finest knives available. In 2007 however, due to fierce […]
Read moreOn Monday, our favorite biotech stock Hemispherx Biopharma (HEB), announced that it had agreed to sell up to $18.3 million in common stock and warrants in a registered offering to two institutional investors. In return for $15 million cash, the new investors received common shares of HEB’s stock at $1.10 per share. Additionally, they will receive Series A warrants to […]
Read moreYou may wonder what Acme United (ACU – $8.00), a ruler and scissors company, has to do with swine flu? Well, Acme United has a division called PhysiciansCare, which offers a wide assortment of first aid kits, over-the-counter medicines, emergency and disaster kits, preparedness products and kit refills. One particular product being sold by PhysiciansCare, are N95 respirators, which are […]
Read moreOur original interest with Hemispherx Biopharma (HEB) was the fact that one of its experimental products was under active review with the United States Food and Drug Administration for the treatment of Chronic Fatigue Syndrome. However, our interest in today’s interview is to discuss the recent events of the spread of swine influenza that is all over the news in […]
Read more